Radha Graham

Radha Graham

Auto-generated profile, based on publicly available information

Radha Graham

Department of Gynaecological Oncology University College London Hospital London UK

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 December 2023 in Journal of Obstetrics and Gynaecology
Verified
Journal Article
Open access
MOM. Olabisi Ogunbiyi
M. Olabisi Ogunbiyi
SOSamuel Oxley
Samuel Oxley
RGRadha Graham
Radha Graham
AOAdeola Olaitan
Adeola Olaitan
The number of patients desiring fertility-preserving treatment for endometrial cancer rather than standard surgical management continues to increase. We aimed to evaluate the efficacies of fertility-preserving treatments on the live birth rate, remission and relapse rates for women with stage 1a grade 1 endometrial carcinoma to support patient counselling. We performed a meta-analysis for our primary outcomes of overall remission and relapse rate, and for secondary analysis, we divided papers into treatment type: systemic progestins, intrauterine progestins or hysteroscopic resection and adjuvant hormonal treatment. Thirty-five observational studies met inclusion criteria, with a total of 624 patients. Overall, conservative treatment of endometrial cancer showed a remission rate of 77% (95% CI: 70-84%), a relapse rate of 20% (95% CI: 13-27%) and a live birth rate of 20% (95% CI: 15-25%) with more favourable outcomes for the hysteroscopic resection group. Hysteroscopic resection and adjuvant hormonal treatment had the most favourable fertility and oncological outcomes. Further high-quality prospective multi-centre trials are warranted to determine the optimal treatment regimen and dosage and risk stratification for these patients.

16 February 2022 in European Journal of Obstetrics & Gynecology and Reproductive Biology
Verified
Journal Article
Closed access
RGRadha Graham
Radha Graham
NMNicola D. MacDonald
Nicola D. MacDonald
MLMichelle Lockley
Michelle Lockley
RMRowan Miller
Rowan Miller
JBJohn Butler
John Butler
MNMiss Claire Newton
Miss Claire Newton

13 May 2024 in International Journal of Cancer
Verified
Journal Article
Open access
OIOjone Illah
Ojone Illah
MSMalcolm Scott
Malcolm Scott
ERElisa Redl
Elisa Redl
JBJames E. Barrett
James E. Barrett
LSLena Schreiberhuber
Lena Schreiberhuber
MWMartin Widschwendter
Martin Widschwendter
Endometrial cancer (EC) is the most prevalent gynaecological cancer in high‐income countries and its incidence is continuing to rise sharply. Simple and objective tools to reliably detect women with EC are urgently needed. We recently developed and validated the DNA methylation (DNAme)‐based women's cancer risk identification—quantitative polymerase chain reaction test for endometrial cancer (WID‐qEC) test that could address this need. Here, we demonstrate that the stability of the WID‐qEC test remains consistent regardless of: (i) the cervicovaginal collection device and sample media used (Cervex brush and PreservCyt or FLOQSwab and eNAT), (ii) the collector of the specimen (gynaecologist‐ or patient‐based), and (iii) the precise sampling site (cervical, cervicovaginal and vaginal). Furthermore, we demonstrate sample stability in eNAT medium for 7 days at room temperature, greatly facilitating the implementation of the test into diagnostic laboratory workflows. When applying FLOQSwabs (Copan) in combination with the eNAT (Copan) sample collection media, the sensitivity and specificity of the WID‐qEC test to detect uterine (i.e., endometrial and cervical) cancers in gynaecologist‐taken samples was 92.9% (95% confidence interval [CI] = 75.0%–98.8%) and 98.6% (95% CI = 91.7%–99.9%), respectively, whilst the sensitivity and specificity in patient collected self‐samples was 75.0% (95% CI = 47.4%–91.7%) and 100.0% (95% CI = 93.9%–100.0%), respectively. Taken together these data confirm the robustness and clinical potential of the WID‐qEC test.

15 March 2024 in The Obstetrician & Gynaecologist
Verified
Journal Article
Open access
PDF file
RGRadha Graham
Radha Graham
NMNicola D MacDonald
Nicola D MacDonald
TMTim A Mould
Tim A Mould
IKIoannis Kotsopoulos
Ioannis Kotsopoulos
Key content Hyperthermic intraperitoneal chemotherapy (HIPEC) at the time of cytoreductive surgery is a proposed additional treatment in the management of advanced tubo-ovarian cancer. Additional organisational approvals, costs, changes to theatre infrastructure and pre-, intra-, and post-operative management considerations are required to implement HIPEC in a clinical setting. Current meta-analysis data suggest that in the setting of interval cytoreductive surgery, HIPEC prolongs overall survival and progression-free survival. There is currently no evidence of benefit in the setting of primary surgery or recurrent disease, but results of ongoing clinical trials are pending. Learning objectives To understand the mechanism of action, safety and efficacy of HIPEC as an adjuvant treatment in tubo-ovarian cancer. Ethical issues Because of variation in treatment protocols and heterogeneity of reported outcomes, HIPEC has not yet been adopted into standard practice. Further studies assessing its benefit, mainly in the setting of primary cytoreduction, are ongoing.

6 September 2022 in European Journal of Surgical Oncology
Verified
Journal Article
Closed access
RGRadha Graham
Radha Graham
IKIoannis Kotsopoulos
Ioannis Kotsopoulos

12 August 2022 in Journal of Pediatric Surgery
Verified
Journal Article
Closed access
RGRadha Graham
Radha Graham
SSSara Stoneham
Sara Stoneham
MLMichelle Lockley
Michelle Lockley
NMNicola D MacDonald
Nicola D MacDonald